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Metabolic syndrome components and their response
to lifestyle and metformin interventions are associated
with differences in diabetes risk in persons with impaired
glucose tolerance
H. Florez1 , M. G. Temprosa2 , T. J. Orchard3 , K. J. Mather4 , S. M. Marcovina5 , E. Barrett-Connor6 ,
E. Horton7 , C. Saudek8,† , X. F. Pi-Sunyer9 , R. E. Ratner10,‡ & R. B. Goldberg11 for the Diabetes
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Aims: To determine the association of metabolic syndrome (MetS) and its components with diabetes risk in participants with impaired glucose
tolerance (IGT), and whether intervention-related changes in MetS lead to differences in diabetes incidence.

Methods: We used the National Cholesterol Education Program/Adult Treatment Panel III (NCEP/ATP III) revised MetS deﬁnition at baseline
and intervention-related changes of its components to predict incident diabetes using Cox models in 3234 Diabetes Prevention Program (DPP)
participants with IGT over an average follow-up of 3.2 years.
Results: In an intention-to-treat analysis, the demographic-adjusted hazard ratios (95% conﬁdence interval) for diabetes in those with MetS
(vs. no MetS) at baseline were 1.7 (1.3–2.3), 1.7 (1.2–2.3) and 2.0 (1.3–3.0) for placebo, metformin and lifestyle groups, respectively. Higher
levels of fasting plasma glucose and triglycerides at baseline were independently associated with increased risk of diabetes. Greater waist
circumference (WC) was associated with higher risk in placebo and lifestyle groups, but not in the metformin group. In a multivariate model,
favourable changes in WC (placebo and lifestyle) and high-density lipoprotein cholesterol (placebo and metformin) contributed to reduced
diabetes risk.
Conclusions: MetS and some of its components are associated with increased diabetes incidence in persons with IGT in a manner that differed
according to DPP intervention. After hyperglycaemia, the most predictive factors for diabetes were baseline hypertriglyceridaemia and both
baseline and lifestyle-associated changes in WC. Targeting these cardiometabolic risk factors may help to assess the beneﬁts of interventions
that reduce diabetes incidence.
Keywords: cardiometabolic risk, diabetes prevention, lifestyle, metformin
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Metabolic syndrome (MetS) consists of clustering risk factors
that may be targeted for risk reduction of cardiovascular
disease (CVD) and diabetes. MetS predicts the incidence of
type 2 diabetes in population-based studies of normoglycaemic
individuals [1, 2]. Whether MetS and its components predict
diabetes in higher risk individuals with impaired glucose
tolerance (IGT) is less well studied. IGT is associated with
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atherosclerosis and increased arterial stiffness, which may lead
to elevated pulse pressure (PP), further increasing the risk
of diabetes and CVD [3, 4]. In addition, the combination of
elevated waist circumference (WC) and triglyceride (TG) – socalled hypertriglyceridaemic waist, has been demonstrated
to be a superior predictor of insulin resistance and intraabdominal fat [5], but its utility as a predictor of incident
diabetes in individuals with IGT has not been assessed. It
is not known whether intervention-associated changes in
these cardiometabolic risk factors will also reduce diabetes
incidence.
The Diabetes Prevention Program (DPP), a multicentre,
randomized controlled trial, showed that the risk of developing
diabetes was reduced 58% by intensive lifestyle (ILS) and
31% by metformin (MET) interventions in people with IGT
compared with placebo (PLA) [6]. The DPP data provide a
unique opportunity to evaluate the associations of MetS and
its components at baseline and their changes after intervention
with the development of diabetes.

Methods
Study Participants
The eligibility criteria, design and methods of the DPP have
been reported elsewhere [6,7]. Selection criteria included: age
≥25 years, body mass index ≥24 kg/m2 (≥22 kg/m2 in Asian
Americans), fasting plasma glucose (FPG) levels between 95 and
125 mg/dl and IGT (2-h post-load glucose of 140–199 mg/dl).
Persons were excluded if they were taking medications known
to alter glucose tolerance or if they had illnesses that could
seriously reduce their life expectancy or their ability to
participate in the trial. This report includes 3234 participants,
who were randomized into three treatment arms, namely ILS,
MET and PLA. Written informed consent was obtained from all
participants before screening, consistent with the Declaration
of Helsinki and the guidelines of each center’s institutional
review board. DPP is registered in www.clinicaltrials.gov
(NCT00004992).
Clinical and Metabolic Variables. Standardized intervieweradministered questionnaires were used to obtain demographic
and clinical data. Blood pressure (BP), weight and WC were
measured biannually using standard techniques. All analytical
measurements for glucose, insulin and lipids were performed
at the Central Biochemistry Laboratory (Northwest Lipid
Research Laboratories, University of Washington, Seattle,
WA) as reported previously. Insulin secretion was estimated
with the corrected insulin response (CIR) = (100 × 30-min
insulin)/[30-min glucose × (30-min glucose – 70 mg/dl)] [8].
Insulin resistance was estimated using the reciprocal of fasting
insulin.
Outcomes. Development of diabetes was determined by an
annual oral glucose tolerance test (OGTT) and semiannual
FPG tests, and required confirmation by a second test using the
diagnostic criteria of the American Diabetes Association and
the World Health Organization [9,10].
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Data Analysis
We classified participants into those with MetS, using
the revised National Cholesterol Education Program/Adult
Treatment Panel III (NCEP/ATP III) definition [11], if
they had three or more of the following criteria: (i) WC
≥40 inches (102 cm) in men or ≥35 inches (88 cm) in
women; (ii) TG ≥1.7 mmol/l (150 mg/dl) or use of lipidlowering medications; (iii) high-density lipoprotein cholesterol
(HDL-C) <1.03 mmol/l (40 mg/day) in men or <1.29 mmol/l
(50 mg/dl) in women or use of lipid-lowering medications; (iv)
systolic BP (SBP) ≥130 mmHg, diastolic BP (DBP) ≥85 mmHg
or use of antihypertensive therapy; and (v) FPG ≥5.6 mmol/l
(100 mg/dl). For comparison, the International Diabetes
Federation (IDF) definition [12] was also used to identify
those with MetS if they had a WC ≥94 cm in men or ≥80 cm
in women plus any two of the following: (i) TGs ≥1.7 mmol/l
or specific treatment for this lipid abnormality; (ii) HDL-C
<1.03 mmol/l in men or <1.29 mmol/l in women or specific
treatment for this lipid abnormality; (iii) SBP ≥130 mmHg
or DBP ≥85 mmHg or treatment of previously diagnosed
hypertension; and (iv) FPG ≥5.6 mmol/l. PP was calculated
from the difference between SBP and DBP measurements at
baseline and in semiannual visits. Hypertriglyceridaemic waist
was defined using the same MetS cut-points for TG and WC.
Participants were followed for an average of 3.2 years. Mean
differences between groups were tested using the t-test, within
groups using the paired t-test and differences in proportions
using the contingency chi-squared test. The normal errors
longitudinal regression model assessed differences between
groups in the mean change from baseline up to the time of
diabetes onset or the last visit, adjusting for baseline values.
The Cox proportional hazards model [13] was used to
assess the association between the covariates and diabetes
onset, adjusting for baseline demographic variables (age at
randomization, sex and race/ethnicity). Multivariate models
were used to examine individual and adjusted contributions of
the MetS components. The Wald test provided p-values and
R2 values for individual covariates, and the likelihood ratio
test tested those for the combined model. Madalla’s partial
R2 described the proportion of variation in risk of diabetes
explained by a covariate, expressed as a percentage [14].
To facilitate comparisons across variables, hazard ratios are
reported for convenient increments approximating 1 standard
deviation of measure. Models were run separately for each
treatment group, and a test of heterogeneity was used to see
if the association differed across treatment groups. Besides
the use of MetS definition based on the dichotomization of
thresholds, we examined the effect of each MetS component
as a quantitative trait to obtain greater granularity on its
specific contribution. In assessing the relationship between
intervention-related changes in components and the risk of
diabetes, the Cox models accounted for differences in age at
randomization, sex, race/ethnicity, baseline FPG and baseline
level. Metabolic variables in the time-dependent proportional
hazards analyses were entered as the average change from
baseline up to, but not including, each visit when diabetes
was diagnosed, and hazard ratios are expressed as a favourable
change approximating 1 standard deviation. The SAS system
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was used for all analyses (SAS Institute, Cary, NC, USA).
Interactions in Cox models were used to assess whether
the association between baseline MetS and incident diabetes
differed by sex, age or race/ethnicity.

Results
We previously reported that baseline MetS prevalence using
the original NCEP/ATP III criteria was 53% [15]. Using the
revised NCEP/ATP III definition, the observed prevalence was
69%, which was similar to a 66% prevalence based on the
IDF definition. Participants who met the NCEP/ATP III MetS
definition were heavier, had greater PP, more insulin resistance
and lower insulin secretion than those without MetS (Table 1),
and there was a greater proportion of Caucasians and fewer
African Americans in this group. Those with MetS at baseline
had higher risk of developing diabetes compared to those
without MetS [HR (95% confidence interval, CI): ILS: 1.7
(1.3–2.3), MET: 1.7 (1.2–2.3) and PLA: 2.0 (1.3–3.0)] (figure
1A). Similar results were observed using the IDF MetS
definition [HR (95% CI): ILS: 1.7 (1.2–2.5), MET: 1.4 (1.1–1.9)
and PLA: 1.7 (1.3–2.2)]. The impact of MetS at baseline did not
differ by treatment group (p = 0.85), age, sex or race/ethnicity.
As expected, participants with baseline fasting hyperglycaemia (≥100 mg/dl) had two to three times higher risk of
developing diabetes compared to those with normal FPG at
baseline in univariate analyses. In addition, abdominal obesity at baseline was associated with higher diabetes risk in the
ILS and PLA groups [PLA: 1.6 (1.1–2.2), p = 0.006; ILS: 1.8
(1.1–2.8), p = 0.02], but not in the MET group. Elevated TGs
were associated with incident diabetes in the MET group only
[1.4 (1.1–1.8), p = 0.02], and low HDL-C was associated with
increased diabetes risk only in the PLA group [1.4 (1.1–1.8),

p = 0.003]. The baseline prevalence of hypertriglyceridaemic
waist was 36.5% and was associated with approximately half
the excess risk of diabetes observed with the full MetS in
the PLA [1.4 (1.1–1.8), p = 0.006] and ILS [1.6 (1.1–2.2),
p = 0.01] groups, but was not significantly associated with diabetes risk in MET participants [1.28 (0.98–1.7), p = 0.07). In
multivariate analysis with demographic factors plus all MetS
components in the model (figure 1B), only high FPG (in all
groups) and abdominal obesity (in ILS and PLA) remained
significantly associated with an increased risk of diabetes. For
each 12 mmHg increment in baseline PP diabetes incidence
was increased by 17% (p = 0.013) and 23% (p = 0.025) in PLA
and ILS participants, respectively, but not in those on MET
(8%, p = 0.3).
In order to have more power to detect the association
between MetS components and incident diabetes, absolute
levels were used (figure 2A, B). For every 8 mg/dl (0.44 mmol/l)
higher FPG at baseline, diabetes risk nearly doubled in PLA
and ILS groups. For each 96 mg/dl (1.1 mmol/l) baseline TG
increment, diabetes incidence was increased by 13% (p = 0.01),
24% (p < 0.001) and 20% (p = 0.013) for the PLA, MET and
ILS groups, respectively; and for every 15 cm greater WC,
diabetes incidence was 36% (p < 0.001) and 52% (p < 0.001)
greater in the PLA and ILS groups, respectively, with no effect
in the MET group. The association between WC and TG on
incident diabetes remained significant after adjusting for FPG
(figure 2B) with the exception of WC in the MET group.
In additional models, there was no significant TG by WC
interaction in any of the treatment groups, and the effects of
TG and WC on diabetes development remained significant after
accounting for baseline values of known diabetes predictors,
namely weight, insulin secretion and insulin sensitivity (data
not shown). TG and WC increments per standard deviation

Table 1. Baseline characteristics by metabolic syndrome status*.

Age (years)
Female
Race
Caucasian [n (%)]
African American [n (%)]
Hispanic [n (%)]
American Indian [n (%)]
Asian [n (%)]
Weight (kg)
Waist circumference (cm)
Systolic BP (mmHg)
Diastolic BP (mmHg)
Pulse pressure (mmHg)
Triglyceride (mmol/l)
HDL-C (mmol/l)
Fasting glucose (mmol/l)
1/fasting insulin
CIR

Overall (n = 3234)

Without MetS (n = 1006)

With MetS (n = 2228)

p-Value

50.6 ± 10.7
2191 (67.7%)

50.9 ± 11.2
669 (66.5%)

50.5 ± 10.4
1522 (68.3%)

0.360
0.308
0.001

1768 (54.7%)
645 (19.9%)
508 (15.7%)
171 (5.3%)
142 (4.4%)
94.2 ± 20.3
105.1 ± 14.5
123.7 ± 14.7
78.3 ± 9.3
45.4 ± 11.8
1.6 (1.1, 2.3)
1.18 ± 0.31
5.9 ± 0.5
0.04 (0.03, 0.06)
0.54 (0.35, 0.80)

498 (49.5%)
228 (22.7%)
165 (16.4%)
65 (6.5%)
50 (5.0%)
86.2 ± 18.2
98.2 ± 13.5
118.1 ± 12.7
75.0 ± 7.9
43.1 ± 10.3
1.2 (0.9, 1.5)
1.38 ± 0.31
5.8 ± 0.5
0.05 (0.04, 0.08)
0.50 (0.31, 0.74)

1270 (57.0%)
417 (18.7%)
343 (15.4%)
106 (4.8%)
92 (4.1%)
97.8 ± 20.1
108.2 ± 13.9
126.3 ± 14.8
79.8 ± 9.5
46.5 ± 12.2
1.9 (1.3, 2.5)
1.09 ± 0.26
6.0 ± 0.4
0.04 (0.03,0.06)
0.56 (0.37, 0.82)

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001

Data are expressed as n (%), mean ± standard deviation, percentage or median (IQR), as appropriate. MetS, metabolic syndrome; BP, blood pressure;
HDL-C, high-density lipoprotein cholesterol; CIR, corrected insulin response; NCEP/ATP III, National Cholesterol Education Program/Adult Treatment
Panel III.
*Metabolic syndrome status is defined using the revised NCEP/ATP III definition.
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A. Model adjusted for demographic factors
Metabolic
syndrome
7.2 →

High FPG
Abdominal obesity
High TG
Low HDL-c
Lifestyle
Metformin
Placebo

High BP
High TG and
Abdominal Obesity
0.5

1.5

2.5

3.5

4.5

5.5

HR for developing diabetes associated with metabolic syndrome components

B. Multivariate model
6.9 →

High FPG

Abdominal obesity

High TG

High BP
Lifestyle
Metformin
Placebo

Low HDL-c

0.5

1.5

2.5

3.5

4.5

5.5

HR for developing diabetes associated with metabolic syndrome components
Figure 1. Demographically adjusted hazard ratio (95% confidence interval, CI) for developing diabetes associated with baseline metabolic syndrome
and components. (A) Model adjusted for demographic factors. (B) Multivariate model. All hazard ratios are adjusted for age randomized, sex and
race/ethnicity. Metabolic syndrome components are defined as: High FPG, fasting plasma glucose ≥100 mg/dl; abdominal obesity, waist ≥102 cm in men
and ≥88 cm in women; high TG, triglycerides ≥150 mg/dl or use of TG-lowering medications; high BP, systolic/diastolic blood pressure ≥130/85 mmHg
or use of antihypertensive medications; low HDL-C, high-density lipoprotein cholesterol <40 mg/dl in men and <50 in women or use of lipid-lowering
medications. High TG and abdominal obesity is defined as TG ≥150 mg/dl and waist ≥102 cm in men (waist ≥88 cm in women).
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A. Baseline components adjusted for demographic factors

C. Changes in components adjusted for demographic factors

FPG (8 mg/dL)*

Waist ( 6 cm )*

Lifestyle
Metformin
Placebo

Waist (15 cm)*

TG ( 69 mg/dL)
TG (96 mg/dl)

SBP ( 11 mmHg)*
SBP (15 mmHg)

DBP ( 8 mmHg)*
DBP (9 mmHg)

Lifestyle
Metformin
Placebo

HDL-c (12 mg/dL)

0.5

0.75

1

1.25

1.5

1.75

2

2.25

HDL-c ( 6 mg/dl)

2.5

0.25

HR for developing diabetes per unit indicated of baseline components

B. Multivariate analysis of baseline components

0.5

0.75

1

1.25

1.5

1.75

2

2.25

HR for developing diabetes per favorable change in components

D. Multivariate analysis of changes in components

FPG (8 mg/dL)*

Lifestyle
Metformin
Placebo

Waist ( 6 cm)*

Waist (15 cm)*
TG ( 69 mg/dL)

TG (96 mg/dl)
SBP ( 11 mmHg)

SBP (15 mmHg)
DBP ( 8 mmHg)*

DBP (9 mmHg)

Lifestyle
Metformin
Placebo

HDL-c (12 mg/dL)

0.5

0.75

1

1.25

1.5

1.75

2

2.25

HDL-c ( 6 mg/dl)

2.5

HR for developing diabetes per unit indicated of baseline components

0.25

0.5

0.75

1

1.25

1.5

1.75

2

2.25

Multivariate HR for developing diabetes per favorable change in components

Figure 2. Hazard ratio (95% confidence interval, CI) for developing diabetes associated with cardiometabolic risk factors as continuous variables. (A)
Baseline components adjusted for demographic factors. (B) Multivariate analysis of baseline components. (C) Changes in components adjusted for
demographic factors. (D) Multivariate analysis of changes in components. All hazard ratios are adjusted for age randomized, sex and race/ethnicity and
computed in increments to approximate 1 standard deviation of the baseline component and of the changes from baseline. Components with an asterisk
(*) denote significant heterogeneity among the treatment groups. Changes in components are computed as the average change from baseline up to, but
not including, each visit when diabetes was diagnosed. To facilitate comparison across variables, hazard ratios are reported.

contributed to more of the variance in incident diabetes (for
WC in the PLA and ILS, respectively, R2 = 1.2 and 2.8%, and
for TG in the PLA, ILS and MET, R2 = 0.7, 0.6 and 1.2%) than
that associated with the category (for PLA and ILS, R2 = 0.7 and
0.6%).
Table 2 shows the changes from baseline for each MetS
component during 3.2 years of intervention according to the
DPP intervention group and their effect on incident diabetes.
Favourable changes in each component were significantly
associated with a reduction in diabetes for all treatment
groups, except for BP and TG in the MET group (figure 2C). In
a multivariate model of baseline and changes in components
(figure 2D), baseline FPG remained the primary determinant
of subsequent diabetes. A reduction in WC of 6 cm decreased
diabetes risk by 45% in the ILS and 23% in the PLA but had
no effect in the MET group. In addition, an increase of 6 mg/dl
(0.16 mmol/l) in HDL-C was independently associated with a
20% reduction in diabetes risk in the MET and PLA groups,
whereas changes in TG values had no effect on incident diabetes
in any group. Unlike baseline WC and TG, the association of
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changes in WC and HDL-C with incident diabetes disappeared
after accounting for changes in weight, insulin secretion and
insulin sensitivity (data not shown). In proportional hazards
model adjusted for demographic and baseline PP, a decrease of
9 mmHg of PP was associated with a reduction in diabetes risk
in the MET (by 18%, p = 0.02) and ILS (by 26%, p = 0.011)
groups but not in those in the PLA group (12%, p = 0.07).
The significant association remained only in the MET group
in the model after further adjustment for changes in HDL, TG
and WC.

Discussion
We found that the baseline presence of MetS, using either
the revised NCEP/ATP III or IDF definitions (66–69% of the
population), was associated with an increased risk of diabetes
by 70–100% in DPP participants with IGT across age, sex,
race and intervention groups. Among cardiometabolic risk
factors studied, increased WC and PP in the ILS and PLA,
and elevated TG in all three groups were each associated with
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Table 2. Mean changes (95% CI) in cardiometabolic risk factors over 3.2 years of follow-up by treatment group.
MetS component

Placebo

Metformin

Intensive lifestyle

Fasting glucose (mmol/l)
Waist circumference (cm)
Systolic BP (mmHg)
Diastolic BP (mmHg)
Pulse pressure (mmHg)
HDL-C (mmol/l)
Triglyceride (mmol/l)

0.21 (0.17, 0.24)
−0.22 (−0.53, 0.094)
−0.68 (−1.21, −0.15)
−1.04 (−1.39, −0.69)
0.41 (−0.03, 0.84)
−0.01 (−0.02, 0)
−0.01 (−0.19, 0.18)

−0.03 (−0.06, 0.0005)*
−1.69 (−2.06, −1.32)*
−0.84 (−1.39, −0.29)
−1.21 (−1.56, −0.86)
0.44 (−0.01, 0.90)
0.01 (0.003, 0.02)*
−0.004 (−0.19, 0.18)

−0.053 (−0.089, −0.017)*
−5.18 (−5.59, −4.77)*, †
−3.37 (−3.94, −2.80)*, †
−3.40 (−3.77, −3.03)*, †
0.14 (−0.30, 0.58)
0.03 (0.02, 0.04)*, †
−0.18 (−0.37, 0.01)*, †

All means are adjusted for the baseline value. MetS, metabolic syndrome; BP, blood pressure; CI, confidence interval; HDL-C, high-density lipoprotein
cholesterol.
*p < 0.05 compared to placebo.
†p < 0.05 compared to metformin.

a higher risk of diabetes, while a change in WC but not TG
predicted diabetes development in the ILS and PLA. Previous
reports have demonstrated that MetS increases diabetes risk
[1, 2] although none assessed diabetes using repeated glucose
measures (OGTT or fasting samples) as was done here. One
study of Mexican Americans and non-Hispanic whites with
IGT found that MetS was associated with incident diabetes
in adults with IGT [2]. Our report extends these observations
to a larger, multiethnic population and explores the effect of
intervention-related changes in MetS components and PP on
risk of progression from IGT to diabetes.
As expected, baseline FPG was the strongest component
linking MetS with incident diabetes. TG levels had additional
predictive properties, as has previously been reported [16],
in all intervention groups. Hypertriglyceridaemia, in this
setting, is thought to reflect mainly the effects of insulin
resistance on adipose tissue, muscle and liver, and is likely not
directly involved in the pathophysiologic pathway to diabetes
development [17], which may explain why changes in TG
were less effective predictors of diabetes risk. However, after
adjustment for weight and surrogates of insulin resistance
and secretion, baseline TG remained a significant predictor,
suggesting an association with diabetes development through
other pathways.
The utility of WC as a predictor of incident diabetes has been
amply demonstrated [18–20]. We found that both baseline and
changes in WC were independently associated with incident
diabetes in the ILS and PLA groups, suggesting that WC may
be directly linked to diabetes development. As the predictive
effect of baseline WC remained significant after adjusting for
glycaemia, insulin resistance and secretion measures, other
pathways, such as inflammation, may also be involved [21]. By
contrast, neither baseline WC nor change in WC was associated
with incident diabetes in the MET group. It is possible that
metformin blunts the effect of obesity on diabetes risk, because
its ameliorative effect on diabetes development occurs mainly
in those in the upper tertile of WC at baseline. Nevertheless,
changes in weight associated with MET treatment contributed
to its ability to reduce diabetes development [22].
TG and WC were the individual cardiometabolic risk
factors that remained associated with incident diabetes
after adjustment for FPG; therefore, participants with both
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abnormalities were especially at risk. Hypertriglyceridaemic
waist was shown to be a simple tool to identify participants
at increased cardiometabolic risk and might better quantify
visceral obesity and its health hazards than WC alone [5].
Hypertriglyceridaemic waist was present in 35% of DPP
participants and was a useful predictor of diabetes in the
ILS and PLA but not the MET group, whether the glucose level
was elevated or not. However, hypertriglyceridaemic waist
does not account for the deleterious effects of incremental
elevations of either TG or WC above categorical cut-points;
therefore, its predictive utility is limited. These findings serve
to emphasize the advantages of evaluating specific MetS
components individually and as continuous variables rather
than as categories.
Although HDL-C has been demonstrated to predict diabetes
[16,23], it was only marginally associated with incident diabetes
in the PLA, whereas an increase in HDL-C was associated
with a reduction of diabetes risk only in the MET and
PLA groups in the multivariate model. The basis for the
inverse association between HDL-C and diabetes development
is poorly understood. Low HDL-C in insulin-resistant states is
thought to be due to remodelling of HDL as a consequence
of hypertriglyceridaemia, and HDL-C has been shown to
correlate strongly with measures of insulin resistance [21].
Why increases in HDL-C in the MET group are associated
with protection against diabetes development, while those
accompanying ILS are not, is also unclear. It is possible that the
effects of saturated fat restriction, which tends to lower HDL-C,
may have confounded the relationship between HDL-C and
diabetes development in the ILS, whereas MET has been shown
to increase HDL-C slightly; this may be linked to its effect on
diabetes prevention.
It is somewhat surprising that baseline BP was not associated
with diabetes development in DPP, as has been previously
reported in a population study [24]. However, baseline PP was
associated with increased risk of diabetes. This is consistent
with a recent report in high-risk Japanese hypertensive patients
showing that PP is an independent predictor of new-onset
diabetes and suggesting that increased arterial stiffness and
microvascular dysfunction are associated with the development
of diabetes [4]. Microvascular dysfunction may contribute to
impaired insulin-mediated changes in muscle perfusion and
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glucose metabolism, providing a framework to understanding
the association among obesity, hypertension and impaired
insulin-mediated glucose disposal [25,26]. Changes in PP were
predictive of diabetes only in the MET group in the multivariate
model. It is conceivable that the effects of lifestyle on diabetes
prevention do not parallel its effects on BP and PP, whereas
in the MET group these effects are more closely aligned [27].
Alternatively, the changes in BP as participants progressed
from IGT to diabetes may be too small to be significant [28].
Others have shown an association of PP with MetS and its
components, particularly in non-diabetic individuals [29], but
more research would be needed to better understand these
associations in the context of patients at high risk of diabetes
and CVD.
In conclusion, the DPP confirmed that the presence of MetS
at baseline is associated with an increased risk of worsening
to diabetes in participants with IGT, most of whom were also
overweight or obese. After adjustment for fasting glucose levels
at baseline, an increased diabetes risk is associated with elevated
WC, PP and TG. Our study evaluated baseline and follow-up
measurement of these cardiometabolic risk factors. Previous
studies relied solely on baseline MetS data to assess diabetes
risk, while we were able to assess the impact that changes
in MetS components resulting from DPP interventions had
on the incidence of diabetes. Favourable lifestyle-associated
changes in waist and HDL-C risk factors are associated with
diabetes risk reduction, whereas in those treated with MET,
changes in PP are predictive of diabetes. Regardless of the
various diagnostic criteria for the MetS and the concerns about
its clinical value [30], our findings underscore the value of
identifying cardiometabolic abnormalities among individuals
with high risk of diabetes as well as targeting them for lifestyle
and other interventions. Recent data analysis suggests that
both lifestyle and pharmacological interventions can reverse
MetS, but the evidence is limited on whether these benefits are
sustained and translate into long-term prevention of CVD and
diabetes [31].
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